Download Image
    
Share
  
Post
Losmapimod for COVID-19
1 study with 48 patients
Hospital Icon Control
Hospital Icon Losmapimod Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Losmapimod studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -18% RCTs -18% Late -18% Favorslosmapimod Favorscontrol
Losmapimod is an oral, small molecule anti-inflammatory drug that selectively inhibits the p38 mitogen-activated protein kinase (MAPK) pathway.
Mar 31
2021
 Ziegler et al., NCT04511819 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Losmapimod in Adult Subjects With COVID-19 (LOSVID STUDY)
18% higher progression (p=0.54) and 14% worse recovery (p=0.64). RCT 52 hospitalized COVID-19 patients showing no significant differences with losmapimod treatment.